Gifted Storyteller’s Journey with Parkinson’s and Other Challenges of a Long Life
Boston, MA, August 25, 2020 — When Parkinson’s disease descended like a dense fog on master storyteller John J. Clayton, he was forced to pivot his perspective, change his expectations and write from a place he calls “… both alive and not alive. Like a kind of ghost …”
Parkinson's Blues: Stories of My Life begins with the arrival of the dark unexpected. In a Monty Python skit, someone in a drab living room complains about being nagged by questions. “I didn’t expect the Spanish Inquisition,” he complains. Suddenly Michael Palin, in red 16th century costume, bursts into the room. “Nobody Expects the Spanish Inquisition!” he shrieks.
Who expects the onset of Parkinson’s? Or cancer? Or stroke? Or the loss of a child? The terrible surprise—the life we didn’t expect—isn’t limited to Parkinson’s. It’s the existential condition of everyone’s life. In fourteen sketches, John J. Clayton links the experience of PD with the experience of childhood sickness, family battles, the struggle to make a good life out of a painful life. The sketches express the hope that we can grow spiritually in the midst of the terrible.
Through 14 eloquent stories — all of which underscore that Clayton’s gift and spirit remain fully intact — Clayton links the onset of Parkinson’s disease with other unexpected, and challenging experiences.
Parkinson’s Blues explores the anticipated pain and unexpected comedy of Parkinson’s in a manner that is deep, graceful and dignified.
Author John J. Clayton has published nine volumes of fiction, both novels and short stories. His collection of interwoven short stories, Minyan, was published in September 2016; his collection Many Seconds into the Future in 2014. Mitzvah Man, his fourth novel, arrived in 2011.
Clayton’s stories have appeared in AGNI, Virginia Quarterly Review, TriQuarterly, Sewanee Review, over twenty times in Commentary, in Notre Dame Review, Missouri Review and The Journal. Two personal essays have been recently published in Jewish Review of Books. His stories have won prizes in O.Henry Prize Stories, Best American Short Stories, and the Pushcart Prize anthology. His Radiance, a collection of stories, was a finalist for the National Jewish Book Award.
Clayton grew up in New York City; received his B.A. at Columbia, his M.A. at NYU and his Ph.D. at Indiana. For much of his career he taught modern literature and fiction writing as professor at the University of Massachusetts, Amherst. He has also written two books of literary criticism: Saul Bellow: In Defense of Man and Gestures of Healing, a psychological study of the modern novel.
Deep Flavors Makes Delicious Kosher Cuisine Accessible for Home Cooks
Dallas, TX, August 25, 2020 — If you love cooking kosher or simply enjoy trying new foods and creating memorable meals in your home kitchen, Deep Flavors: A Celebration of Recipes for Foodies in a Kosher Style from Kenneth M. Horwitz offers an abundance of tempting dishes designed for cooks, whether Kosher or non-Kosher, with helpful tips for proper preparation.
“Cooking is worth some effort and attention to detail,” Horwitz writes. “The positive reactions from family or guests, as well as your own enjoyment, will make it worthwhile.”
“Effort” and “attention to detail,” however, don’t have to equate with “difficult.” In fact, throughout Deep Flavors, Horwitz shares his wisdom for sourcing ingredients and breaking recipes into simple steps — and how to do some of this prep work well in advance so that delicious meals can be served in spite of hectic schedules.
Between the covers of Deep Flavors, Horwitz offers an eclectic menu that includes traditional Jewish dishes plus other regional and international favorites reinterpreted to observe some or all of the rules for kosher foods. The result is a diverse anthology of recipes that will appeal to broad audiences everywhere — Jewish and otherwise.
Horwitz, a CPA by trade, explained in an interview with Today’s CPA that, “My approach to cooking is really an extension of what I do in my professional practice. I solve problems. One of the ‘problems,’ at least in my house, is that since we maintain a kosher house, but eat eclectically, is how to convert recipes so that they are kosher …”
Horwitz’s Texas State Fair Blue Ribbon-winning Spinach/Mushroom Lasagna, for instance, is a completely original vegetarian lasagna accessible to Jews and vegetarians, with a unique twist on ingredients that gives it a complex flavor profile. Even recipes for classic foods such as brisket and roast turkey contain newly imagined taste combinations and techniques to elevate them while maintaining recognizable hallmarks of each dish. Another recipe that epitomizes the standard set by Horwitz, yet remarkably simple to execute, is the Dill French Toast: savory, unique, and delicious.
Horwitz’s ultimate goal was to create recipes that are easy to read and easily followed by any-one with a basic knowledge of cooking. He provides detailed instructions with enhanced explanations and alternatives, additive for both the novice and the more experienced cook.
A Readers’ Favorite reviewer, who gave Deep Flavors a 5-star rating, referred to the book as “… an essential addition to any cookbook fanatic's collection and to anyone who believes in spending the time and effort to make the ‘food’ experience a real work of art …”
With 51 years in a general tax and transaction practice as a CPA and lawyer, Ken Horwitz developed a creative and focused approach to finding and fixing problems — a skill that translates well to the development of and modification of recipes based on traditional family favorites but tailored to one’s personal tastes and dietary needs.
His professional drive and the care given to his work have earned him multiple awards, including the Honorary Fellow for a lifetime of distinguished service and the 2017 Chairperson of the Year by the Texas Society of CPAs. Currently residing in Dallas, Texas, Horwitz enjoys sharing his passion for cooking with his wife and his children’s families. Horwitz believes that one of the highest compliments he has received came from a longstanding client who uses numerous lawyers. He said, “Ken, you are the only lawyer we use whose work we have not had to fix.” Horwitz’s goal is for Deep Flavors to reach that same standard.
Deep Flavors Publisher: Inspire on Purpose ISBN-13: 978-1-941782-51-4 ISBN-10: 1-941782-51-5 Available from Amazon.com
###
The Train It Right Life - Over Training, Responsibility and Egos - Welcome back to another episode of my podcast! This weeks episode I talk about how people tend to want to do more and more and end up over training, taking ownership/responsibility to both things that happen for you and to you as well as men and their egos! Enjoy!
4 Tips to Bounce Back From Running Injuries Faster
Injuries are bound to happen at some point. It can be frustrating to have to stop running because you have suffered an injury. However, if you take the proper steps, then you will be able to bounce back in no time. There are several things that you can do in order to recover from an injury.
Get Therapy
Physical therapy is beneficial for both major and minor injuries, especially when related to the movement of joints and ligaments. Specialized care offered in services like assistive stretching therapy can help strengthen your legs against future inflammation as well as help your legs heal correctly from current issues. Therapy also gives you valuable insight into stretches and warmups you can continue on your own to help maintain the health of your body during future runs.
Get Rest
It can be frustrating to have to rest and take it easy. However, this is one of the best things that you can do in order to recover more quickly. Resting allows your body to naturally repair itself. This means not taking on tough runs too early, keeping your legs elevated and using alternating heat and cool pads to reduce inflammation, and getting plenty of sleep to encourage regenerative healing.
Keep Moving
Even though it is important to rest, you do not want to spend all of your time in the bed. Getting the right amount of exercise for the healing process is all about maintaining a balance. Gentle exercises like those prescribed in physical therapy help promote blood flow and keep your legs flexible during the healing process. Casual walks also help encourage your legs to take on weight again without stressing the injury. As long as you avoid aggravating the injury and keep your exercises small, regular exercise can be an extremely beneficial part of the healing process.
Follow a Healthy Diet
It can be tempting to load up on comforting junk food while you are at home recovering. However, it is important for you to follow a nutritious diet. A healthy diet is essential for healing as it gives your body what it needs to repair itself. Fruits, vegetables and whole grains are great for keeping up your energy and fighting infections, while plenty of lean protein gives your body the building blocks to repair damaged tissue. Excess sugar and empty carbs, however, can slow down your healing process by increasing inflammation.
Recovering from a sports injury can be quite difficult. However, you can speed up the process by stretching, getting the rest you need and engaging in physical activity. You will also need to eat a healthy diet. Additionally, it is a good idea for you to get a massage on a regular basis.
True Story of Survival Opens Minds and Dialogues about Mental Health
New York NY, August 20, 2020 — Mark Henick stood precariously on the wrong side of the railing on a crumbling, concrete overpass. The bridge spanned two realities and, for Henick, had become a symbol of escape — in one form or another. A voice behind him tried to help. A crowd gathered. Siren lights flashed in his peripheral vision. Surrounded but still alone, Henick let go.
So-Called Normal: A Memoir of Family, Depression and Resilience from Mark Henick is a vital and triumphant story of perseverance and recovery by one of North America’s foremost advocates for mental health
Henick’s near-death experience on the overpass that night would alter his emotional orbit just enough that his exit from a psychiatric ward following that suicide attempt in 2003 would be his last. His transformation didn’t happen overnight — it was a gradual process punctuated with new challenges and setbacks — but slowly, his patterns reversed and he began a profound, “upward” spiral toward recovery.
So-Called Normal chronicles Henick’s youth and the events that led to that fateful night on the bridge and the experiences and transformation that followed. It is a vivid and personal account of a boy who had to deal with the breakdown of his parents’ marriage, an abusive stepfather, bullying and trauma — all while trying to navigate his progressively worsening mental health. In the backdrop is a community that didn’t talk about mental illness, one where silence and maintaining the comforts of “normal” was paramount. So-Called Normal is not a “misery memoir” about suicide — it’s a gripping, inspirational story of survival.
Author Mark Henick’s TEDx talk about being saved from death by a stranger is one of the most watched in the world and has been viewed millions of times. His search for “the man in the brown jacket” whose bravery and strong arms kept him from falling to his death went viral around the world (and was successful!). Henick has been on television and radio and has written many articles on mental health. He has hosted more than 60 intimate conversations about mental health with notable public figures and celebrities on his podcast, So-Called Normal, and has executive produced and hosted the Living Well podcast for Morneau Shepell. Henick has served on the board of directors for the Mental Health Commission of Canada, and was the president of a provincial division of the Canadian Mental Health Association — the youngest person in either role. He has worked as a frontline clinician, a program manager and the national director of strategic initiatives for CMHA. Currently the CEO and principal strategist for Strategic Mental Health Consulting, Mark Henick is in high demand as an international keynote speaker on mental health recovery.
Tech Innovation to Improve Resiliency and Agility Will Be Critical Post-COVID-19, Says Lux Research
Five key trends are shaping the future of tech innovation across all industries
BOSTON, MA, August 20, 2020 – COVID-19 has drastically changed the landscape for businesses across all industries, forcing immediate changes – but ones that will have long-term consequences. In the latest report by Lux Research, “The Impact of COVID-19 on Tech Innovation,” Lux outlines five key trends that will define how the world beyond the pandemic will be different.
The five trends that are shaping the post-COVID-19 future are infection prevention, remote commerce, improving resiliency, greater agility, and macroeconomic impacts. Each of these trends can have a positive or negative influence on an emerging technology. By considering the effects of these trends on technology, we can see how industries are being transformed.
“The methodology focuses on three primary parts: identifying the major trends shaping the future after the pandemic, assessing the impact on technology, and prioritizing the actions that need to be taken based on trends and tech impacts,” explains Michael Holman, Ph.D., Vice President of Research at Lux Research and co-author of the report. “While things are changing too rapidly to have 100% certainty, this methodology helps executives take a systematic approach to rebalancing their portfolio.”
Lux predicts that increased agility and resilience will drive long-term positive change for materials innovation. “Materials informatics will also see a medium-term positive impact thanks to increased efficiency and agility in R&D. We expect a positive effect on plastic waste recycling and synthetic biology, as more people are gravitating to single-use plastics to stay safe, and synbio can allow more agile and flexible production,” says Holman.
The energy industry will see a number of key changes. Lux predicts that increased resilience and agility will drive further investments in clean energy, spurring on the energy transition. Bio-based and synthetic fuels, however, will be hard-hit by macroeconomic funding constraints and low oil prices. With increased energy use out of the home thanks in part to remote working conditions, home energy management is predicted to have a positive medium-term impact, led by remote commerce and improved resiliency.
“Digital transformation will rapidly accelerate adoption of emerging technologies like telemedicine, thanks to a dramatic increase in remote commerce and the need for infection prevention,” notes Kevin See, Ph.D., Vice President of Research at Lux Research and co-author of the report. “Wearables will also see a positive near-term lift as they aid in infection prevention and reopening efforts. There will be an upward trend in robotics due to the need for infection prevention and improving resiliency. COVID-19 will push major manufacturing and logistics operations to assess the potential of robotics moving forward.”
The agrifood and health ecosystems will see positive growth in omics, which are a powerful suite of technologies for fighting COVID-19. In food, ingredient informatics and plant-based proteins will benefit, as they allow for increased resilience and agility in the food value chain.
The future of the mobility industry is more varied. Autonomous vehicles will experience a long-term positive impact due to social distancing preferences but near-term are delayed due to disruption of development and pilots. Shared mobility is a mixed bag, as ride-hailing is severely negatively affected in the near term, while micromobility solutions provide an alternative that better suits social distancing measures. The long-term consequences for electric vehicles will be minimal, as adoption will continue to be driven by regulations that for now have not drastically changed.
By using this framework, innovation leaders can identify the trajectory of technologies they are either invested in or considering investing in, and the implications for their industry. Some technology outlooks will see persistent effects from COVID-19, while others will experience a more dynamic shock that changes over time. Understanding the effects of the underlying trends on that trajectory will aid in making better decisions with more confidence.
Lux Research is a leading provider of tech-enabled research and advisory services, helping clients drive growth through technology innovation. A pioneer in the research industry, Lux uniquely combines technical expertise and business insights with a proprietary intelligence platform, using advanced analytics and data science to surface true leading indicators. With quality data derived from primary research, fact-based analysis, and opinions that challenge traditional thinking, Lux empowers clients to make more informed decisions today to ensure future success.
Significant advancement achieved with ARDS-003 sterile injectable
nano-emulsion finished drug product.
A new anti-inflammatory drug candidate.
Ottawa, August 13, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has awarded the contract for the manufacturing of its active pharmaceutical ingredient (API), HU-308, and of the intravenous, sterile, finished drug product ARDS-003 to Dalton Pharma Services (Dalton).
HU-308 is a synthetic small molecule new chemical entity which specifically targets the human CB2 receptors and has the potential to be a new anti-inflammatory drug. Dalton has developed and improved the synthesis process for HU-308. In preparation for moving the clinical program forward, additional activities are underway which include manufacturing drug batches of HU-308 and ARDS-003. This allowed Tetra to carry out the nonclinical safety program and studies required to generate the data needed for a clinical trial application in both Canada and the USA. The development of a GMP batch manufacturing process is ongoing along with a first scale-up to fulfill Tetra’s clinical requirements. To-date, the drug specifications and analytical quality control methods for the release of both the API and injectable formulation are completed and in the final validation stage. The placebo and active injectable formulations have been developed using FDA approved excipients for intravenous emulsions which will avoid additional toxicology testing to qualify the non-medicinal ingredients. The first injectable product batches were shown to have adequate particle size for sterile filtering and filter compatibility. Sterile filtering is the optimal method for obtaining a sterile injectable drug.
"Dalton is pleased to be working with Tetra on this important new drug to potentially treat cytokine release syndromes. Dalton will play an important role in the development of this innovative drug and we look forward to a long and productive partnership with Tetra," said Peter Pekos, CEO, Dalton Pharma Services.
Dr. Guy Chamberland, CEO and CRO commented, "We are very pleased to be working with Dalton on this high priority project to bring ARDS-003 into clinical trials. This partnership was ideal for Tetra as Dalton recognized the urgency and proposed a plan that aligns with our corporate objective to bring this investigational drug into clinical trials as soon as possible. More importantly, this plan ensured that all aspects of the regulatory requirements and GMP compliance were respected. As a pharmaceutical company, the progress achieved at this point, and within such an accelerated timeframe is significant in that we can now attest that ARDS-003 conforms to the standard quality and compatibility requirements of other injectable prescription drugs for human use".
About Dalton:
Dalton Chemical Laboratories Inc. o/a Dalton Pharma Services is a Health Canada approved and FDA registered cGMP contract service provider of integrated chemistry, drug development and manufacturing services to the pharmaceutical and biotechnology industries. Dalton brings over 30 years of experience to their client's projects and emphasizes quality, speed and flexibility.
Dalton can accelerate a drug development program by integrating drug discovery, formulation and process development, custom synthesis, cGMP sterile fill/finish of liquids and powders, cGMP API manufacturing and/or dosage form manufacturing and Accelerated Stability Testing, all at a single location that helps Dalton to be adaptable, flexible and cost-effective.
CMO 2016, 2017 and 2018 Leadership Awards in the categories of Quality, Reliability, Capabilities, Expertise, Compatibility and Development from Life Science Leader reflects Dalton's ongoing commitment to their clients, peers and the business community. In 2017 Dalton was re-certified as "A Great Place to Work."
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed and approved, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
Neither the TSX Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research and development strategies, including the success of this product or any other product, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
How to Avoid Inflammation After Workouts
Inflammation is nothing new for those who hit the gym regularly. When you work out your muscles, they get surrounded by blood as they try and heal. This inflammation can be painful, but fortunately there are ways to reduce the swelling and pain. Here are just a few ways to reduce or avoid inflammation after a hearty workout.
Ice It Down
When it comes to reducing swelling in the body, ice is the key. Having a cold temperature on the area helps to restrict the blood flow to your muscles. The trick is ensuring that you don’t spend too much time in the cold. It’s only recommended to do a maximum of 20 minutes with ice on a specific body part. After this time frame, your body will start to go into protective mode thinking that it’s getting frostbite. This will have an adverse effect that actually causes the body to purposefully cause inflammation in order to heat up. To avoid this, simply stick to 20 minutes maximum for any icing session.
Use A CBD Product
With the wide emergence of CBD in the United States market, more and more studies have been conducted on its overall health benefits. While many are still in the debating phase, one thing has been shown to be proven true about this substance. It works great for reducing inflammation in the body. You can get CBD into your bloodstream in multiple ways such as hemp CBD lotion, pills, edible gummies, and tinctures.
Get A Massage
When you find yourself in the hours after a tough workout, you want to do everything possible to reduce the amount of inflammation that your body undergoes. Getting a massage is one great way to alleviate muscle tension and allow blood to freely move throughout your body. You’ll want to pick the right type of massage to encourage healing and not induce inflammation. A Swedish massage is more preferred over other techniques like a deep-tissue massage.
Use Anti-Inflammatories
Anti-inflammatory medications can be utilized to reduce the amount of swelling that happens in your body and joints. These include over the counter medications like naproxen, ibuprofen, and aspirin. While these aren’t recommended for daily use, they can be extremely helpful when you’ve undergone a very rough workout.
Working out is a great way to keep your energy flowing and your body in shape. However, inflammation can put a real damper on your workout regimen. That is unless you utilize the tips outlined above to avoid post-workout inflammation so you can get back into the gym more often.
Brooke Chaplan is a freelance writer and blogger. She lives and works out of her home in Los Lunas, New Mexico. She loves the outdoors and spends most of her time hiking, biking, and gardening. For more information, contact Brooke via Facebook at facebook.com/brooke.chaplan or Twitter @BrookeChaplan
Pancreatic cancer - Promising Treatment for Deadly Cancer Blocked by Canadian Regulators
TORONTO, Aug. 19, 2020 /CNW Telbec/ - While innovations in health care are spurring extraordinary advances in the treatment of malignant tumours, progress has been limited when it comes to the world's toughest cancer. Pancreatic Cancer Canada is fighting to raise survival rates for pancreatic cancer patients through targeted investments in research, increased awareness and patient support, community activation and advocacy initiatives. Pancreatic cancer is the third leading cause of cancer-related deaths for Canadians in 2020. It has an exceptionally low five-year survival rate of just 8%. A diagnosis of pancreatic cancer means a 92% likelihood of death – a fact that has not changed significantly in over 40 years. Pancreatic cancer outcomes are worsening amid rising survival rates for most other cancers. Statistics show that 50% of those who are diagnosed with pancreatic cancer will die 4 months after diagnosis.
While new first-line treatments are becoming available to patients, disease progression after initial therapy is common, leaving patients with no options for further treatment, making it nearly impossible to halt the progression of this terrible cancer.
Significant therapeutic progress
In the modern era of cancer research, pancreatic cancer has proven to be among the most unyielding of adversaries. While advancements have been made in expanding our understanding of this cancer, the 5-year survival rate has not changed materially in the past 40 years, and nearly all diagnosed patients ultimately succumb to the diseasei.
Today, with positive results of a large Phase 3 clinical trial NAPOLI-1 with ONIVYDE (irinotecan liposome), some hope is possible. An innovative pancreatic cancer treatment, it has been shown to extend patients' overall survival by 45% while maintaining the quality of life for pancreatic cancer patients.
Onivyde is already funded in a number of countries and is recommended by the National Comprehensive Cancer Network's (NCCN) international guidelines. Onivyde has also recently received a fast-track designation from the US Food and Drug Administration (FDA) as a first-line combination treatment for metastatic pancreatic cancer.
An innovative treatment unavailable in Canada
In 2017, Health Canada granted regulatory approval of PrONIVYDE® (irinotecan liposome for injection) for the treatment of metastatic pancreatic cancer, in combination with standard chemotherapy medications, in adult patients who have disease progression following first-line treatment.
It is now more than three years later and this drug is still not available in Canada despite receiving positive recommendations from the pan-Canadian Oncology Drug Review (pCODR) and the Quebec Institut national d'excellence en santé et en services sociaux (INESSS).
Given the slow progress against this disease, one must ask the question, 'Why are our regulatory authorities waiting to fund the only new drug approved recently by Health Canada that has shown promise in pancreatic cancer?'
Pancreatic Cancer Canada (PCC), believes it is time for Canada to catch up to other countries in the treatment of pancreatic cancer and adds its voice to those of patients and doctors across the country who have already articulated their support for the funding of PrONIVYDE® directly with pCODR and INESSS, and continue to demand that this medication be reimbursed as soon as possible. We have a clear expectation that the pan-Canadian Pharmaceutical Alliance (pCPA) fulfill its mandate to negotiate drugs approved by Health Canada and to rapidly establish public funding across Canada.
Quotes
"Pancreatic Cancer Canada is very concerned by the delay in making approved medications for pancreatic cancer available to Canadians – delays that are costing patients their lives. We urgently request that provincial representatives on the negotiating committee amend their processes to prioritize the survival of pancreatic cancer patients over administrative needs. This system of delays and blocked access threatens to discourage critical research efforts, as well as significant investments by pharmaceutical companies who bring viable treatment options to our patients." Michelle Capobianco, Chief Executive Officer, Pancreatic Cancer Canada
"Canada needs to catch up with other industrialized countries and provide options for patients progressing from their first-line treatment. Introducing new treatment options in Québec would provide the oncology community with new tools to help patients continue in their fight against this devastating disease." Petr Kavan MD, PhD, Medical Oncologist, Segal Cancer Center Jewish General Hospital
"PrONIVYDE® offers patients a chance at better outcomes, through demonstrated efficacy in treating metastatic pancreatic cancer. There is a treatment within our reach to prolong the survival of patients without compromising their quality of life, and it's important that we make it accessible and without any further delay." Rebecca Prince, MBBS, FRACP, MSc, Medical Oncologist, University Health Network
"My husband did not live long enough to see a treatment developed that could save him. Pancreatic cancer patients today do not have the luxury of time. That is why we are asking for an end to the senseless delays in bringing promising drug treatments to the market. It is unbearable to know that there is an approved drug at our fingertips that could extend the lives of our loved ones – and yet, we can't access it. This is not how we will improve, and ultimately end, this deadly cancer." Joanne Furino, family caregiver
About Pancreatic Cancer Canada (PCC)
Pancreatic Cancer Canada is fighting to raise survival rates for the world's toughest cancer investing in targeted research, increased awareness and patient support, community activation and advocacy. We have taken on one of the world's deadliest cancers - a disease with virtually no progress in survival in the past 40 years and a 92% mortality rate. We are aggressively fighting it with investments in research aimed at greater understanding of this cancer and better treatment options. At the same time, we are working to educate physicians about faster diagnosis and with patients/families to support them as they face the realities of this cancer in their lives.
Alithya to Implement Oracle Cloud for Nemours Children's Health System
ALPHARETTA, GA, Aug. 19, 2020 /CNW Telbec/ - Alithya Group inc. (NASDAQ: ALYA) (TSX: ALYA) ("Alithya"), a leader in strategy and digital transformation employing more than 2,100 highly-qualified professionals and offering enterprise solutions throughout the United States, Canada, and Europe, has been selected by Nemours Children's Health System to support the implementation of Oracle Cloud for its finance and accounting, supply chain, human resource management, payroll, and reporting needs.
"We believe the combination of Oracle's world-class technology and Alithya's industry expertise will enable us to improve financial margins, optimize our health system for growth, and eliminate redundancy in systems and processes," stated Bernie Rice, Chief Information Officer and Enterprise Vice President at Nemours.
More than ever, the healthcare industry faces challenges and pressures unlike any other sector of the economy. As an Oracle Platinum Partner with a dedicated healthcare practice, Alithya supports Oracle solutions that provide the transparency and agility that healthcare organizations need to meet these new challenges head on.
"Alithya is proud to partner with Nemours for this project," said Russell Smith, President, Alithya USA. "Our multi-phased approach will effectively meet Nemours' business needs and demands by providing a core Human Capital Management (HCM) and Recruiting solution, a core Enterprise Resource Planning (ERP) system, and Enterprise Performance Management (EPM)."
About Nemours Children's Health System Nemours is an internationally recognized children's health system that owns and operates the two free-standing children's hospitals: the Nemours/Alfred I. du Pont Hospital for Children in Wilmington, Del., and Nemours Children's Hospital in Orlando, Fla., along with outpatient facilities in five states, delivering pediatric primary, specialty and urgent care. Nemours also powers the world's most-visited website for information on the health of children and teens, KidsHealth.org, and offers on-demand, online video patient visits through Nemours CareConnect.
About Alithya Alithya Group inc. is a leader in strategy and digital transformation in North America. Founded in 1992, the Company can count on more than 2,100 professionals in Canada, the US and Europe. Alithya's integrated offering is based on four pillars of expertise: strategy services, application services, enterprise solutions and data and analytics. Alithya deploys solutions, services, and skillsets to craft tools tailored to its clients' unique business needs in the Financial Services, Manufacturing, Energy, Telecommunications, Transportation and Logistics, Professional Services, Healthcare, and Government sectors. Corporate responsibility is at the heart of Alithya's management approach, and as such, the company is an advocate for good governance, workforce diversity and development, environment-friendly practices and social involvement in communities. To learn more, go to alithya.com.
SOURCE Alithya
TRAIN IT RIGHT NEWSLETTER
Sign Up and get a free 7 day Train it Right HIIT Program!
